{"id":"W4389231326","doi":"10.1182/blood-2023-178885","title":"Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM): Results from Part 1 of the Phase 2 Apex Trial","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Daiichi Sankyo Europe; Astellas Pharma; Genentech; Actuate Therapeutics; Sierra Oncology; Incyte; Gilead Sciences; Actinium Pharmaceuticals; ARUP Laboratories; Ono Pharmaceutical; Mateon Therapeutics; Jazz Pharmaceuticals; Celgene; Karyopharm Therapeutics; Constellation Pharmaceuticals; Agios Pharmaceuticals; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Systemic mastocytosis; Medicine; Internal medicine; Clinical endpoint; Midostaurin; Gastroenterology; Progressive disease; Phases of clinical research; Tyrosine-kinase inhibitor; Randomized controlled trial; Clinical trial; Oncology; Leukemia; Chemotherapy; Bone marrow; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001631314,0.0008532705,0.001824632,0.0002364433,0.0002643676,0.001182146,0.0006460142,0.001041677,0.002663946],"category_scores_gemma":[0.001439125,0.0003786173,0.001307981,0.0003199622,0.0005149917,0.0008696425,0.0003583388,0.002826989,0.000696102],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008445957,"about_ca_system_score_gemma":0.0008062418,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004746793,"about_ca_topic_score_gemma":0.001452531,"domain_scores_codex":[0.9994891,0.0002119357,0.00003754497,0.0000976943,0.00007052363,0.00009323798],"domain_scores_gemma":[0.9991129,0.0002144888,0.0002204305,0.00006562184,0.00009566844,0.0002909063],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7986751,0.008837905,0.01733891,0.001331372,0.002280178,0.0003749667,0.0002700821,0.00337873,0.0219541,0.0003984707,0.0117529,0.1334074],"study_design_scores_gemma":[0.7441545,0.1995986,0.03940344,0.0001533616,0.001800276,0.0009112697,0.0001270827,0.002764953,0.002912129,0.0007067912,0.007395469,0.0000722734],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9833072,0.009509086,0.0003598129,0.000939301,0.0001491042,0.0006186871,0.002213592,0.00007015077,0.002832937],"genre_scores_gemma":[0.9892877,0.003266639,0.0006305529,0.001166536,0.0002120416,0.0005523979,0.003689796,0.00002177761,0.001172437],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002663946,"threshold_uncertainty_score":0.008911788,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008231757814372818,"score_gpt":0.206977026345693,"score_spread":0.1987452685313202,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}